Why the study?
Do ET-1 and big ET-1 preserve their vasoactive potency, and is big ET-1 converted to ET-1 in patients with end-stage renal disease on hemodialysis?
Population
58 chronic hemodialysis patients, including 21 with ischemic heart disease, 32 without ischemic heart…
Comparison
Intravenous infusion of ET-1 and big ET-1 in a… vs ET-1 versus big ET-1 infusion; HD patients with…
Design
Cohort
Authors
Loading...
Supports potential ET-1 contribution to ESRD hypertension; leaves open therapeutic implications pending randomized evidence.
Do ET-1 and big ET-1 preserve their vasoactive potency, and is big ET-1 converted to ET-1 in patients with end-stage renal disease on hemodialysis?
ET-1 and big ET-1 retain their vasoactive properties and big ET-1 is converted to active ET-1 in end-stage renal disease, potentially contributing to uremic cardiovascular complications.
Ottosson-Seeberger et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: